Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-08-21, Stock:JNJ, The news for the past five days is as follows:
2020-08-14: NEWS1: Johnson & Johnson stock outperforms market on strong trading day.NEWS2: Coronavirus Latest: Friday, August 14.NEWS3: Coronavirus update: Europe, UK strike vaccine deals; antibody therapies on the rise.NEWS4: Vaccine Checkup: JNJ, AstraZeneca, Novavax reach COVID-19 vaccine deals.NEWS5: FOCUS-Vaccine makers including Moderna must hit U.S. timing goals for full payments.NEWS6: Johnson & Johnson, Novavax ink vaccine deal with UK.NEWS7: Novavax and Johnson & Johnson to Supply U.K. With Covid-19 Vaccines.NEWS8: Schools struggle to reopen as COVID-19 cases rise.NEWS9: U.K. strikes two Covid-19 vaccine deals for 90 million doses.NEWS10: Britain lines up more potential COVID-19 vaccine supplies with J&J, Novavax deals.NEWS11: UK buys potential COVID-19 vaccines from J&J and Novavax.
2020-08-17: NEWS1: Johnson & Johnson stock outperforms market on strong trading day.NEWS2: Iconic Johnson & Johnson Is Poised for an Upside Breakout.NEWS3: Covid-19 Vaccine Push Lacks a Key Ingredient: Trust.
2020-08-18: NEWS1: Report: States Pushing for $26.4 Billion Settlement With Drug Companies Over Opioid Liability.NEWS2: Johnson & Johnson stock outperforms market on strong trading day.NEWS3: EXPLAINER-World Health Organization's struggle for a global COVID-19 vaccine plan.NEWS4: Drug-Distributor Stocks Rise as Opioid Settlement Looks Closer After Report on More Talks.NEWS5: Brazil greenlights human trials for J&J's potential COVID-19 vaccine.NEWS6: Brazil approves human trials for potential Johnson & Johnson COVID-19 vaccine.NEWS7: U.S. states seek $26.4 bln from drug firms in opioid litigation - WSJ.
2020-08-19: NEWS1: SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Momenta Pharmaceuticals, Inc. (Nasdaq - MNTA).NEWS2: SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc..NEWS3: Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite Directions.NEWS4: Johnson & Johnson stock outperforms market on strong trading day.NEWS5: Why Momenta Pharmaceuticals Stock Rocketed 69% Higher Today.NEWS6: Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5 Billion in Cash.NEWS7: US STOCKS-S&P 500, Nasdaq hit record highs as Apple crosses $2 trillion mark.NEWS8: Could Momenta Deal Give Johnson & Johnson Breakout Momentum?.NEWS9: MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout.NEWS10: Dow Jones Up As Apple Stock Makes History; S&P 500, Nasdaq Hit New Highs.NEWS11: Looking Into Johnson & Johnson's Return On Capital Employed.NEWS12: US STOCKS-S&P 500, Nasdaq hit record highs as Apple tops $2 trillion in market value.NEWS13: Johnson & Johnson -- Moody's affirms J&J's Aaa rating; negative outlook.NEWS14: Johnson & Johnson Is Buying Momenta Pharmaceuticals. Both Stocks Are Gaining..NEWS15: Stocks move modestly higher, S&P 500 clinches new intraday high.NEWS16: P/E Ratio Insights for Johnson & Johnson.NEWS17: US STOCKS-S&P 500 notches record high for second day after Target, Lowe's results beat.NEWS18: Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion.NEWS19: J&J $6.5 Billion Momenta Pact Is Year’s Biggest Pharma Deal.NEWS20: Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion; Buy with Target Price $170.NEWS21: Johnson & Johnson Buys Biotech Momenta Pharmaceuticals for $6.5 Billion.NEWS22: US STOCKS-Wall St set to open higher after solid results from Lowe's, Target.NEWS23: Johnson & Johnson's Debt Overview.NEWS24: J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta.NEWS25: (MNTA) Alert: Johnson Fistel Investigates Proposed Sale of Momenta Pharmaceuticals; Are Shareholders Getting a Fair Price?.NEWS26: JNJ To Buy Momenta Pharma In $6.5B All-Cash Deal; MNTA Up 70%.NEWS27: Don't Buy Johnson & Johnson (NYSE:JNJ) For Its Next Dividend Without Doing These Checks.NEWS28: Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson.NEWS29: J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta.NEWS30: Johnson & Johnson to buy Momenta for about $6.5 billion.NEWS31: Johnson & Johnson to buy Momenta for about $6.5 bln.NEWS32: Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases.NEWS33: PRESS DIGEST - Wall Street Journal - Aug. 19.
2020-08-20: NEWS1: J&J Borrows $7.5 Billion for Momenta in Latest M&A Bond Sale.NEWS2: Johnson & Johnson to Launch Late-Stage Coronavirus Vaccine Trials in September.NEWS3: Johnson & Johnson stock rises Thursday, outperforms market.NEWS4: Johnson & Johnson Sets Late-Stage Vaccine Trial Next Month.NEWS5: Coronavirus Latest: Thursday, August 20.NEWS6: ETFs in Focus on Momenta Buyout Deal With JNJ.NEWS7: Johnson & Johnson to test coronavirus vaccine in 60,000 volunteers.NEWS8: J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence.NEWS9: Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative.NEWS10: CureVac Stock Up as EU Talks on Coronavirus Vaccine Advance.NEWS11: 2 Big Pharma Stocks That Robinhood Investors Really Like -- and You Should, Too.

Answer: Rise